No Data
Haemonetics: Strong Market Position and Attractive Investment Opportunity Amid Growth in Plasma and Hospital Segments
Investors Three-year Returns in Haemonetics (NYSE:HAE) Have Not Grown Faster Than the Company's Underlying Earnings Growth
Should You Continue to Hold TMO Stock in Your Portfolio?
Are Investors Undervaluing Haemonetics (HAE) Right Now?
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Haemonetics Initiated at Overweight by JP Morgan